"Designing Growth Strategies is in our DNA"

Contraceptive Drugs Market Size, Share & COVID-19 Impact Analysis, By Product (Oral (Combined Contraceptives and Progestin-only Pills), Injectable, and Patches), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Clinics, Online Channels, Public Channels & NGOs, and Others), and Regional Forecast, 2023-2030

Region : Global | Format: PDF | Report ID: FBI100063



Play Audio Listen to Audio Version

The contraceptive drugs market size was valued at USD 17.50 billion in 2022 and is projected to grow from USD 18.57 billion in 2023 to USD 31.30 billion by 2030, exhibiting a CAGR of 7.7% during 2023-2030. North America dominated the global market with a share of 39.37% in 2022.

An ever-increasing concern regarding the rapidly increasing population globally, especially in low and middle-income countries is leading to the growing focus on educating the general population about available methods of contraception.

The increasing focus of leading market players and healthcare agencies on creating awareness of contraception methods is the primary factor augmenting the contraceptive drugs market growth.

  • For instance, in September 2022, Mankind Pharma’s regular oral contraceptive brand – Unwanted 21 - launched a multilingual campaign on the occasion of the World Contraception Day.

  • Similarly, in September 2021, Bayer AG in the Middle East partnered with the United Nations population fund in Egypt to launch the 'Your Right to Plan' campaign on the World Contraception Day. The main motive of this campaign was to provide 100 million women in underprivileged regions with modern contraception and elevate the demand for family planning services.

This factor has been pivotal in increasing awareness among the general population, especially in emerging countries, toward the adoption of contraception and available contraceptive options. Furthermore, the introduction of over-the-counter drugs and other products by domestic and global players resulted in higher adoption and fueled the market growth.


COVID-19 Pandemic Hampered Sales of Contraceptive Drugs Which Restricted the Market Growth

The emergence of the COVID-19 pandemic hindered the demand for contraceptive drugs across the world. A majority of the key players operating in the market recorded a significant decline in their revenues from the sales of these drugs due to the COVID-19 pandemic.

  • For instance, Bayer AG registered a revenue of USD 797.6 million from the sales of YAZ hormonal contraceptive drugs in 2020 compared to USD 810.7 million in 2019, a decline of 1.6% from 2019-2020.

This significant decline in revenues was attributed to several factors, including supply chain disruptions and others. Further, significant disruption was observed in family planning and contraception services in many countries. According to a pulse survey by the World Health Organization in 2020, it was reported that around 59% of the total surveyed countries reported partial disruption, and 9% of the countries reported severe disruption in family planning and contraception services during the pandemic. Similarly, according to a survey published by the Global Financing Facility (GFF) in June 2020, the number of women who might lose access to family planning in the 36 countries was around 26 million, leading to approximately 8 million unintended pregnancies.

However, according to a number of survey analysis and interviews with key opinion leaders, it was reported that lockdown relaxations and the resumption of family planning sessions in developing countries resulted in substantial growth during 2020-2021.


Shift from Conventional to Modern Contraceptive Methods Resulting in the Transformation of the Market

Technological advancements and the rising awareness of modern contraceptive methods are shifting the preference from traditional methods toward modern ones, including oral contraceptive pills, injectables, and topical drugs.

Conventional drugs and procedures offer limited protection against sexually transmitted diseases and have a higher failure rate than modern methods. Thus, this leads to the increasing demand and adoption of modern techniques such as sterilization, pills, and other products among the general population.

  • For instance, according to the National Family Health Survey report published in May 2022, employed women are more likely to use modern contraception in India. The survey stated that 66.3% of employed women use a modern contraceptive method compared to 53.4% of unemployed women.

  • Additionally, according to the data published by the United Nations in 2019, Department of Economic and Social Affairs, Population Division, a total of 1.9 billion women of reproductive age (15-49 years) are present across the world. Around 842 million women now use modern contraception methods, including oral drugs and injectables, and approximately 80 million consumers are using traditional methods.

  • Also, according to the data published by CHASE Africa in 2021, it was reported that oral contraceptive drugs accounted for 45.3% of family planning uptake in 2020.

Request a Free sample to learn more about this report.

This factor indicates that the growing preference of consumers toward modern methods, including drugs, is anticipated to surge the demand and adoption of these drugs during the forecast period.


Growing Awareness Regarding Contraceptive Drugs Leads to Product Demand 

There is a rising focus of non-profit organizations and regional and national healthcare agencies on improving women’s reproductive health and sexual wellness through various campaigns and public awareness programs. These for-profit and non-profit organizations promote the use of contraception techniques and create awareness among the general population toward various contraception methods, including a growing preference for these drugs.

  • For instance, in December 2020, the government of Ireland announced a plan to introduce free contraception to women aged between 17 and 25.

  • Additionally, according to the article published by Ms. Magazine in July 2021, it was reported that oral contraceptive drugs are made available over the counter without a prescription in the U.K.

Available Reimbursement Policies in Developed Countries to Fuel Market Growth

Furthermore, the rising number of products being introduced in the market by leading global and domestic players and the availability of favorable reimbursement policies in the developed regions are supporting the market growth.

According to an article published by BBC in 2021, it was reported that a three-month supply of progestogen-only pills was provided to women across Scotland for free by community pharmacies. Also, according to NHS U.K., the women population in the U.K. can avail contraceptive injections free from contraceptive clinics, GP surgeries, and others.

These initiatives by the government and other organizations are fueling the adoption rate of these drugs and are instrumental for growth of this market during the study period.


Side Effects Associated with Drugs to Limit Product Demand

The long-term use of birth control medications is associated with side effects such as bleeding, headaches, nausea, and weight gain. Several research studies have been published to highlight the long-term side effects related to birth control drugs.

  • For instance, according to the study published by the American Cancer Society (ACS) in 2021, long-term consumption of birth control pills increases breast and cervical cancer risk.

  • Moreover, progesterone and estrogen-based drugs are linked with increasing the risk of developing a blood clot, which may cause stroke and heart attack.

Moreover, lack of awareness and social taboo about contraception methods and other methods of contraception are accountable for the lower adoption of these products in developing countries. Moreover, the availability of alternative contraceptive methods, including condoms, IUDs, and other physical barriers that are proven to be effective for contraception without any side effects, is anticipated to hinder the adoption rate of these drugs.


By Product Analysis

To know how our report can help streamline your business, Speak to Analyst

Oral Segment to Dominate Owing to its Robust Demand for Consumable Drugs

Based on product, the market is segmented into oral, injectable, and patches. The oral segment is further categorized into combined contraceptives and progestin-only pills.

The oral segment accounted for the highest market share, driven by higher adoption of oral drugs in developed and developing countries across the globe. The surge in demand is attributable to the undue clinical benefits of oral medicines over other contraceptive methods, including injectable and patches. Also, the easy administration of oral pills along with growing availability of these products in pharmacies, public hospitals, and others, is also fostering the adoption rate of this segment during the study period.

  • According to a research article published by NCBI in 2022, it was stated that the women population in Brazil has free access to contraception, and the Unified Health System offers a large variety of contraceptive products, including combined and progestin-only oral pills, free of cost.

  • Also, according to the United Nations, the number of women of reproductive age consuming birth control pills increased from around 97 million in 1994 to 151 million in 2019.

Furthermore, increasing number of product approvals is also anticipated to supplement the segment growth. For instance, in November 2022, the U.S. FDA approved Lupin’s Drospirenone tablets that are used for the prevention of pregnancy. This product is the generic equivalent of Exeltis USA Inc's Slynd tablets.

The injectable segment is expected to witness a significant CAGR during the forecast period. The comparatively lower annual cost of injectable products compared to drugs and pills leads to higher demand for injectable products.

By Distribution Channel Analysis

Increasing Preference of Customers toward Over-the-Counter Drugs has Enabled the Dominance of the Retail Pharmacy Segment

The market is categorized into hospital pharmacy, retail pharmacy, clinics, online channels, public channels & NGOs, and others based on distribution channel.

The retail pharmacy segment dominated the global market in 2022. The dominance of the retail pharmacy segment is attributed to the growing demand for OTC contraception drugs among the general population and increasing awareness about various contraception methods. Several countries, including Brazil, Mexico, China, and India, allow birth control pills to be sold over the counter. This factor has led to a higher preference of consumers toward retail pharmacies for procuring birth control pills. Moreover, favorable regulatory policies are also responsible for the growth of the retail pharmacy distribution channel.

  • For instance, according to the report published by the National Alliance of State Pharmacy Associations (NASPA), more than 15 jurisdictions and states in the U.S. have allowed pharmacists to prescribe and provide drugs and other products for contraception.

The online channels segment is growing at a CAGR higher than the other sub-segments. The higher growth of online channels is attributed to the rising adoption of over-the-counter solutions combined with various online offers and discounts to attract customers. Also, a wide distribution channel and all-time availability of these drugs, including oral pills, injectables, and patches of different brands are the other key factors for the highest CAGR of this segment.


North America Contraceptive Drugs Market Size, 2022 (USD billion)

To get more information on the regional analysis of this market, Request a Free sample

The market in North America registered a value of USD 6.89 billion in 2022. The high awareness about birth control pills in the North American population combined with the growing childbearing women population and fertility rate in the region are some of the major factors responsible for the dominance of North America in 2022.

  • According to the data published by Macrotrends LLC in 2022, it was reported that the fertility rates for the U.S. and Canada were around 1.78 and 1.50 births per woman, respectively, in 2021.

Europe held the second-largest contraceptive drugs market share due to the presence of a well-established healthcare infrastructure and an increasing number of women opting for modern contraceptive methods, including patches and injectables.

  • According to an article published by European Medical Group LTD in 2021, it was reported that in an Italian study of 177 women using a contraceptive patch, 88% of the users found it convenient.

The Asia Pacific market is expected to register the highest CAGR during the forecast period. The increasing government initiatives to expand access to contraceptive drugs, and surge in awareness about pills surge the increasing demand for these drugs. Moreover, the growing emphasis on family planning with the rise in cases of unintended pregnancy is influencing the market for birth control pills, including other contraceptive options.

  • According to an article published by Living Media India Limited in 2022, it was reported that around 121 million unintended pregnancies are reported each year in the world, and more than one in seven such pregnancies occurred in India. Thus, the rising cases of unintended pregnancies are responsible for the increasing adoption of different methods of contraception, including drugs, patches, and injectable products to avoid unwanted pregnancies.

To know how our report can help streamline your business, Speak to Analyst

Latin America and the Middle East & Africa accounted for a significant share of the global market. Increasing initiatives by the government and other organizations for the awareness of contraceptive drugs are elevating the adoption rate in this region among the women population. This factor is anticipated to drive market growth during the forecast period.


Top Market Players Focus on Strategic Collaborations to Gain a Competitive Advantage over Other Players 

The global market is fragmented, with the presence of a few international players and a large number of domestic generic drug manufacturers. The major players operating in the market focus on strategic collaborations to gain a competitive advantage over other players. Leading three to four players together accounted for a lower market share in 2022.

Also, the market is characterized by key players, including Agile Therapeutics and Amneal Pharmaceuticals LLC. These companies focused on introducing advanced drug molecules and patches to increase their product portfolio and strengthen their brand name.

  • For instance, in January 2022, Agile Therapeutics, Inc. partnered with Afaxys Pharma, LLC to expand the availability of Twirla in the U.S. Twirla is a low-dose and effective non-invasive patch.



  • August 2023 – Lupin received the U.S. FDA approval for its Turqoz (Norgestrel and Ethinyl Estradiol Tablets USP). This is a generic equivalent of Wyeth Pharmaceuticals LLC's Lo/Ovral-28 tablets.

  • July 2023 - The U.S. FDA approved Opill (norgestrel) tablet, the first non-prescription oral contraceptive for daily use. This product is manufactured by Laboratoire HRA Pharma, recently acquired by Perrigo Company plc.

  • November 2022 – Drospirenone tablets manufactured by Lupin received tentative approval from the U.S.FDA for its abbreviated new drug application (ANDA). This product is a generic oral contraceptive pill.

  • October 2022 – Bayer AG received a grant from the Bill & Melinda Gates Foundation for pre-clinical research in novel non-hormonal contraception.

  • July 2022 - Mithra Pharmaceuticals, SA and Mayne Pharma Group Limited announced that NEXTSTELLIS – an oral contraceptive with a novel estrogen, is now available in Australia.


An Infographic Representation of Contraceptive Drugs Market

To get information on various segments, share your queries with us

The contraceptive drugs market research report provides a detailed analysis of the market. It focuses on key aspects such as leading companies, products, and distribution channels. Besides this, it offers insights into the market trends and highlights key industry developments. In addition to the abovementioned factors, the report encompasses several factors that have contributed to the market growth in recent years.

Report Scope & Segmentation



Study Period


Base Year


Estimated Year


Forecast Period


Historical Period


Growth Rate

CAGR of 7.7% from 2023-2030


Value (USD billion)


By Product, Distribution Channel, and Region

By Product

  • Oral

    • Combined Contraceptives

    • Progestin-only Pills

  • Injectable

  • Patches

By Distribution Channel


  • Hospital Pharmacy

  • Retail Pharmacy

  • Clinics

  • Online Channels

  • Public Channels & NGOs

  • Others

By Region

  • North America (By Product, By Distribution Channel, and By Country)

    • U.S. (By Product)

    • Canada (By Product)

  • Europe (By Product, By Distribution Channel, and By Country/Sub-region)

    • U.K. (By Product)

    • Germany (By Product)

    • France (By Product)

    • Italy (By Product)

    • Spain (By Product)

    • Scandinavia (By Product)

    • Rest of Europe (By Product)

  • Asia Pacific (By Product, By Distribution Channel, and By Country/Sub-region)

    • Japan (By Product)

    • China (By Product)

    • India (By Product)

    • Australia (By Product)

    • Southeast Asia (By Product)

    • Rest of Asia Pacific (By Product)

  • Latin America (By Product, By Distribution Channel, and By Country/Sub-region)

    • Brazil (By Product)

    • Mexico (By Product)

    • Rest of Latin America (By Product)

  • Middle East & Africa (By Product, By Distribution Channel, and By Country/Sub-region)

    • GCC (By Product)

    • South Africa (By Product)

    • Rest of Middle East & Africa (By Product)

Frequently Asked Questions

Fortune Business Insights says that the global market size stood at USD 17.50 billion in 2022 and is projected to reach USD 31.30 billion by 2030.

In 2022, the market size in North America was USD 6.89 billion.

The market will exhibit steady growth at a CAGR of 7.7% during the forecast period (2023-2030).

By product, the oral segment will lead the market.

Increasing focus on creating awareness through public programs, growing insurance coverage, and introducing OTC contraceptive products are the key drivers of the market.

Johnson & Johnson Services, Inc., AbbVie Inc., and Bayer AG are the top players in the market.

North America dominated the market in 2022.

The surge in demand for effective prevention of pregnancy, increased adoption of innovative products, and a growing awareness among the female population base are some of the factors expected to drive the adoption of these products.

Seeking Comprehensive Intelligence on Different Markets?
Get in Touch with Our Experts

Speak to an Expert
  • Sep, 2023
  • 2022
  • 2019-2021
  • 151


  • $4850

Personalize this Research

  • Granular Research on Specified Regions or Segments
  • Companies Profiled based on User Requirement
  • Broader Insights Pertaining to a Specific Segment or Region
  • Breaking Down Competitive Landscape as per Your Requirement
  • Other Specific Requirement on Customization
Request Customization Banner

Client Testimonials

“This report is really well done and we really appreciate it! Again, I may have questions as we dig in deeper. Thanks again for some really good work.”

- U.S.-based biotechnology company focussing on treatment of chronic pain.

“Kudos to your team. Thank you very much for your support and agility to answer our questions.”

- Europe-based provider of solutions to automate data centre operations.

“We appreciate you and your team taking out time to share the report and data file with us, and we are grateful for the flexibility provided to modify the document as per request. This does help us in our business decision making. We would be pleased to work with you again, and hope to continue our business relationship long into the future.”

- India-based manufacturer of industrial and specialty intermediates with a strong global presence.

“I want to first congratulate you on the great work done on the Medical Platforms project. Thank you so much for all your efforts.”

- One of the largest cosmetics company in the world.

“Thank you very much. I really appreciate the work your team has done. I feel very comfortable recommending your services to some of the other startups that I’m working with, and will likely establish a good long partnership with you.”

- U.S. based startup operating in the cultivated meat market.

“We received the below report on the U.S. market from you. We were very satisfied with the report.”

- Global hearing aids manufacturer.

“I just finished my first pass-through of the report. Great work! Thank you!”

- U.S. based solar racking solutions provider.

“Thanks again for the great work on our last partnership. We are ramping up a new project to understand the imaging and imaging service and distribution market in the U.S.”

- World’s leading advisory firm.

“We feel positive about the results. Based on the presented results, we will do strategic review of this new information and might commission a detailed study on some of the modules included in the report after end of the year. Overall we are very satisfied and please pass on the praise to the team. Thank you for the co-operation!”

- Germany based machine construction company.

“Thank you very much for the very good report. I have another requirement on cutting tools, paper crafts and decorative items.”

- Japanese manufacturing company of stationery products.

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . Privacy.